Experts preview ASTRO 2026 presentations to watch, including those on SOFT Preop, PSMAgRT, radiosurgery for depression, and AI tools for patient safety.
Press Release|Articles|July 24, 2025
ACRO Accreditation Again Receives ISO:9001 2015 Certification
Author(s)ACRO
ACRO's Accreditation Program has completed and passed its annual surveillance by the International Standards Organization.
Advertisement
The American College of Radiation Oncology’s Accreditation Program has completed and passed its annual surveillance by the International Standards Organization (ISO). ACRO Accreditation is the only U.S. radiation oncology accrediting body to achieve ISO 9001:2015 Certification.
The ISO is a highly regarded international certification body which evaluates an organization’s processes and procedures. The program undergoes a comprehensive yearly review of its quality objectives, operations, and structure.
Advertisement
Related to this article
Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.
As part of the ANDA pathway, Bravnetsa is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to the reference product, Lutathera.
ASTRO’s first standalone clinical practice guideline for bladder cancer recommends trimodal therapy vs radical cystectomy for select muscle-invasive disease cases.
Lutetium Lu 177 dotatate injection has been approved by the FDA for patients with somatostatin receptor-positive GEP-NETs.
Data from the phase 3 LITESPARK-011 trial support the FDA approval of belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma.
In the phase 1b portion of the MELT-MM trial, elranatamab plus mezigdomide produced a 100% overall response rate in relapsed/refractory multiple myeloma.
Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full approval.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA MCGP Panel Votes in Favor of the Galleri Multicancer Early Detection Test
2
Approaching Cardiovascular Risk in Prostate Cancer Hormonal Therapy
3
FDA Grants Approval to Lirafugratinib for Advanced Cholangiocarcinoma with FGFR2 Alteration
4
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
5